Handling side-effects of targeted therapies: safety of targeted therapies in solid tumours.
Elez
E
E
Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Macarulla
T
T
Tabernero
J
J
D000970:Antineoplastic Agents / Q000009:adverse effects*; D016503:Drug Delivery Systems / Q000009:adverse effects*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D066246:ErbB Receptors; D047428:Protein Kinase Inhibitors; D018719:Erb-b2 Receptor Tyrosine Kinases; D042461:Vascular Endothelial Growth Factor A